by business segment
| Fresenius Medical Care | Fresenius Kabi | Fresenius Helios | Fresenius Vamed | Corporate/Other | Fresenius Group | |||||||||||||
| in million € | 2008 | 2007 | Change | 2008 | 2007 | Change | 2008 | 20071) | Change | 2008 | 20071) | Change | 20083) | 20071) | Change | 2008 | 2007 | Change |
| Sales | 7,213 | 7,093 | 2% | 2,495 | 2,030 |
23% | 2,123 | 1,841 | 15% | 524 | 408 | 28% | -19 | -14 | -36% | 12,336 | 11,358 | 9% |
| thereof contribution to consoli- dated sales |
7,209 | 7,089 | 2% | 2,458 | 1,986 | 24% | 2,123 | 1,841 | 15% | 524 | 408 | 28% | 22 | 34 | -35% | 12,336 | 11,358 | 9% |
|
thereof intercom- pany sales |
4 | 4 | 0% | 37 |
44 | -16% | 0 | 0 | – | 0 | -41 | -48 | 15% | 0 | 0 | |||
|
contribution to consoli- dated sales |
59% | 62% | 20% | 18% | 17% | 16% | 4% | 4% | 0% | 0% | 100% | 100% | ||||||
| EBITDA |
1,419
|
1,418 | 0% | 544 | 408 | 33% | 251 |
220 |
14% | 35 | 31 | 13% | 11 | -47 | 123% | 2,260 |
2,030 | 11% |
|
Depreciation and amorti- zation |
282 | 265 | 6% | 101 | 76 | 33% | 76 | 65 | 17% | 5 | 5 | 0% | 319 | 10 | -- | 783 | 421 | 86% |
| EBIT | 1,137 | 1,153 | -1% | 443 | 332 | 33% | 175 | 155 | 13% | 30 | 26 | 15% | -308 | -57 | -- | 1,477 | 1,609 | -8% |
| Net interest | -229 | -271 | 15% | -145 | -49 | -196% | -60 | -53 | -13% | 6 | 6 | 0% | -3 | -1 | 200% | -431 | -368 | -17% |
| Net income | 556 | 523 | 6% | 200 | 183 | 9% |
80 | 64 | 25% | 26 | 23 | 13% | -592 |
-383 | -55% | 270 | 410 | -34% |
|
|
||||||||||||||||||
| Operating cash flow | 691 | 875 |
-21% |
205 | 179 |
15% |
225 |
202 |
11% | 27 | 72 | -63% | -74 | -32 | -131% | 1,074 | 1,296 | -17% |
| Cash flow before acquisitions and dividends | 233 | 479 | -51% | 83 | 67 | 24% |
94 | 65 | 45% | 23 | 68 | -66% | -95 | -45 | -111% | 338 | 634 | -47% |
|
|
||||||||||||||||||
| Total assets | 10,720 | 9,626 | 11% | 6,240 | 2,310 | 170% | 3,092 | 3,072 | 1% | 469 | 390 | 20% | 23 | -74 | 131% | 20,544 | 15,324 | 34% |
| Debt | 4,123 | 3,833 | 8% | 4,288 | 1,121 | -- |
1,090 | 1,136 | -4% | 2 | 0 | -716 | -391 | -83% | 8,787 | 5,699 | 54% | |
| Capital expenditure | 467 | 418 | 12% | 137 | 116 | 18% | 135 | 149 | -9% | 4 | 4 | 0% | 21 | 13 | 62% | 764 | 700 | 9% |
| Acquisitions | 220 | 262 | -16% | 3,612 | 178 | -- | 5 | 174 | -97% | 35 | 6 | -- | -19 | -2 | -- | 3,853 | 618 | -- |
|
|
||||||||||||||||||
| Research and development expenses | 55 | 49 | 12% | 109 | 86 | 27% | – | 1 | -100% | 0 | 0 | 315 | 48 | -- | 479 | 184 | 160% | |
| Employees (per capita on balance sheet date) | 68,050 | 64,662 | 5% | 20,457 | 16,964 | 21% | 30,088 | 30,043 | 0% | 2,802 | 1,767 | 59% | 820 | 745 | 10% | 122,217 | 114,181 | 7% |
|
|
||||||||||||||||||
| Key figures |
|
|||||||||||||||||
|
EBITDA margin |
19.7% | 20.0% | 21.8% | 20.1% | 11.8% | 12.0% | 6.7% | 7.6% | 17.9%4) | 17.9% | ||||||||
|
EBIT margin |
15.8% | 16.3% | 17.8% | 16.4% | 8.2% | 8.4% | 5.7% | 6.4% | 14.0%4) | 14.2% | ||||||||
| Deprecia- tion and amortiza- tion in % of sales |
3.9% | 3.7% | 4.0% | 3.7% | 3.6% | 3.5% | 1.0% | 1.2% | 3.9%4) | 3.7% | ||||||||
| Operating cash flow in % of sales |
9.6% | 12.3% | 8.2% | 8.8% | 10.6% | 11.0% | 5.2% | 17.6% | 8.7% | 11.4% | ||||||||
| ROOA |
12.3% | 12.5% | 8.9%2) | 17.7% | 6.3% | 5.6% | 22.2% | 22.8% | 9.8%2) | 11.4% | ||||||||
| 1) | Prior year’s segment data have been adjusted according to the new company structure as of January 1, 2008. |
| 2) | The underlying pro-forma EBIT does not include special items from the acquisition of APP Pharmaceuticals, Inc. (APP). |
| 3) | including special items from the APP acquisition |
| 4) | before special items from the APP acquisition |
| The segment reporting is an integral part of the Notes. | |
| The following Notes are an integral part of the Consolidated Financial Statements. | |